Innovative Leadership Clairity is led by founder and CEO Connie Lehman, who has gained significant industry recognition including a spot on the TIME100 Health List, demonstrating strong leadership and influence in healthcare innovation which can be leveraged for strategic partnerships and collaborations.

Traction and Funding Having raised $43 million in Series B funding and generating an estimated revenue between $10M and $25M, Clairity is positioned as a rapidly growing company with proven investor confidence, making it an attractive client or partner for advanced medical technology solutions.

Technology Edge Clairity’s FDA-authorized AI platform for breast cancer risk prediction offers a competitive advantage in precision diagnostics, providing opportunities to collaborate with healthcare providers seeking state-of-the-art screening technologies.

Market Engagement Active participation in major industry events such as RSNA 2025 and BIO International Convention indicates a focus on market visibility and thought leadership, presenting opportunities for outreach to key stakeholders and decision-makers in radiology and healthcare.

Growth in Healthcare Sector With a focus on improving screening accuracy and reducing healthcare costs, Clairity aligns well with hospitals, health systems, and insurance companies aiming to adopt innovative AI solutions, opening avenues for technology integration and service expansion.